Advertisement

Torax Medical closes a $30 million Series D funding round in support of its sphincter augmentation products, designed to treat gastroesophageal reflux disease.

Torax Medical logo

Torax Medical closed a $30 million Series D funding round in support of its acid reflux treatment products.

The funds will go toward expanding commercialization of the St. Paul, Minn.-based medical device company's sphincter augmentation systems, including Torax's platform Magnetic Sphincter Augmentation devices.

Advertisement
Advertisement